Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, PR China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, PR China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 1;1174:122728. doi: 10.1016/j.jchromb.2021.122728. Epub 2021 Apr 24.
Rehmanniae Radix Preparata (RR) and Corni Fructus (CF), well-known traditional Chinese medicines (TCMs), were generally used together in the clinical practices to treat chronic kidney disease (CKD) with synergistic effects for thousands of years, but their combination mechanism remains largely unknown so far. Recent evidences have implicated intestinal flora as potential targets for the therapy of CKD. In this study, the CKD rat model was induced by adenine. The levels of proteinuria, serum creatine (SCr), blood urea nitrogen (BUN) and creatinine clearance (Ccr) were used to assess the cooperation effect of RR and CF. Furthermore, high-throughput 16S ribosomal RNA (rRNA) gene sequencing combined with fecal metabonomics based on UPLC-Q-TOF-MS/MS were applied to explore the variations of intestinal flora and their metabolic profiles. 16S rRNA gene sequencing data indicated that CKD rats treated with RR, CF and RC showed the differences in the composition of gut microbiota. The abundance of beneficial bacteria including Ruminococcaceae UCG-014, Ruminococcus 1, Prevotellaceae_NK3B31_group, Lachnospiraceae NK4A136 group and Lachnospiraceae UCG-001 were elevated in various degrees, while the opportunistic pathogen such as Desulfovibrio was markedly decreased after the treatment. Moreover, fecal metabolite profiles revealed 15 different metabolites associated with CKD. These metabolites were mainly involved in the related metabolic pathways such as amino acid metabolism, bile acids metabolism and glycerophospholipid metabolism. The results implied that gut flora and their metabolites might play a vital role in the progress of CKD, which provided a potential target for the development of novel drugs for the therapy of CKD.
熟地黄(RR)和山茱萸(CF)是两种著名的中药,几千年来一直被广泛用于临床实践中联合治疗慢性肾脏病(CKD),具有协同作用,但它们的联合作用机制至今仍知之甚少。最近的证据表明,肠道菌群可能是治疗 CKD 的潜在靶点。本研究采用腺嘌呤诱导 CKD 大鼠模型。通过检测蛋白尿、血清肌酐(SCr)、血尿素氮(BUN)和肌酐清除率(Ccr)水平来评估 RR 和 CF 的协同作用。此外,采用高通量 16S 核糖体 RNA(rRNA)基因测序结合基于 UPLC-Q-TOF-MS/MS 的粪便代谢组学方法,探讨肠道菌群的变化及其代谢谱。16S rRNA 基因测序数据表明,RR、CF 和 RC 治疗的 CKD 大鼠肠道微生物群落组成存在差异。有益菌(如 Ruminococcaceae UCG-014、Ruminococcus 1、Prevotellaceae_NK3B31_group、Lachnospiraceae NK4A136 group 和 Lachnospiraceae UCG-001)的丰度在不同程度上升高,而机会致病菌(如脱硫弧菌)的丰度则明显降低。此外,粪便代谢谱揭示了 15 种与 CKD 相关的不同代谢物。这些代谢物主要参与氨基酸代谢、胆汁酸代谢和甘油磷脂代谢等相关代谢途径。结果表明,肠道菌群及其代谢物可能在 CKD 进展中发挥重要作用,为开发治疗 CKD 的新型药物提供了潜在靶点。